Actelion not for sale; looking at acquisition candidates (translated)
Story
Actelion, the listed Swiss biopharmaceutical company, is looking at acquisition candidates, the Finanz und Wirtschaft reported.
The Swiss bi-weekly asked Actelion Chief Executive Jean-Paul Clozel if he was looking at Santhera Pharmaceuticals, to which Clozel said he was looking at all companies with innovative products but declined to reveal details.
Clozel also stated that Actelion itself was not for sale though.
The report noted that Actelion has almost CHF 1bn cash reserves.
Source Finanz und Wirtschaft